| DIRECT COMPETITOR COMPARISON | |
| ISIS | AVII | ENZ | GNTA.OB | Industry | | Market Cap: | 1.08B | 161.24M | 196.46M | N/A | 163.44M | | Employees: | 300 | 83 | 539 | N/A | 95 | | Qtrly Rev Growth (yoy): | -9.10% | 22.80% | 15.80% | N/A | 20.50% | | Revenue (ttm): | 118.99M | 17.92M | 89.57M | N/A | 46.74M | | Gross Margin (ttm): | -1.31% | -25.49% | 43.22% | N/A | 68.58% | | EBITDA (ttm): | -16.09M | -11.56M | -17.75M | N/A | -7.12M | | Oper Margins (ttm): | -19.54% | -72.90% | -23.68% | N/A | 2.25% | | Net Income (ttm): | -11.27M | -29.82M | -23.56M | N/A | N/A | | EPS (ttm): | 1.617 | -0.358 | -0.628 | N/A | -0.17 | | P/E (ttm): | 6.80 | N/A | N/A | N/A | 18.38 | | PEG (5 yr expected): | 0.25 | N/A | N/A | N/A | 1.04 | | P/S (ttm): | 9.25 | 9.12 | 2.27 | N/A | 4.37 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.21 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | ENZ | | ENZO BIOCHEM INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
Fri 6:00am -
EDGAR Online | | • | ENZ | | Enzo Biochem, Inc. Announces Departure of Its Secretary and Treasurer
Wed, Nov 25 -
Business Wire | | • | AVII | | AVI BioPharma, Inc. Presents Update on AVI-4658 at TREAT-NMD / NIH International Conference
Thu, Nov 19 -
Marketwire | | • | AVII | | AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative (TMTI) Industry Day
Wed, Nov 18 -
Marketwire | | • | ENZ | | Enzo Biochem's Clinical Lab Enters Exclusive Agreement with GeneNews to Market Blood Test for Colorectal Cancer
Wed, Nov 18 -
Business Wire | | • | ENZ | | Enzo Biochem Executive to Discuss Oral Immune Regulation Platform at Windhover TA Partnerships 2009 Conference
Fri, Nov 13 -
Business Wire | | • | AVII | | AVI BIOPHARMA INC Financials
Fri, Nov 13 -
EDGAR Online Financials | | • | ENZ | | Enzo Biochem to Present at Lazard Capital Markets 6th Annual Healthcare Conference
Wed, Nov 11 -
Business Wire | | • | AVII | | AVI BioPharma loses $8.1M in Q3
Mon, Nov 9 -
at bizjournals.com | | • | AVII | | AVI BioPharma Announces Third Quarter 2009 Financial Results & Corporate Highlights
Mon, Nov 9 -
Marketwire | | • | GNTA.OB | | Genta Announces Closing of $10 Million in Two Offerings of Common Stock and Convertible Notes
Fri, Sep 4 -
Business Wire | | • | GNTA.OB | | Hot Biotech Events for Next Week: BioBuzz
Fri, Sep 4 -
at TheStreet.com | | • | GNTA.OB | | GENTA INC DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,
Wed, Jul 8 -
EDGAR Online | | • | GNTA.OB | | GENTA INC DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Tue, Jun 30 -
EDGAR Online | | • | GNTA.OB | | GENTA INC DE/ Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Fri, Jun 5 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
